ArticleArchives of Razi Institute2023
Estimation of Interleukin 32 and Interleukin 37 Serum Levels in Iraqi Patients with Rheumatoid Arthritis.
Article in Archives of Razi Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Role of IL-32 in RA pathology and potential as a drug target.Frontiers in immunology · 2026Review
- Natural compounds and mesenchymal stem cells: implications for inflammatory-impaired tissue regeneration.Stem cell research & therapy · 2024Review
- Association Between Serum Interleukin-32 Level and Disease Status in Cases with Neuromyelitis Optica Spectrum Disorders.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune condition characterized by persistent inflammation in synovial joints. Interleukine-32 (IL32) is known to have significant pro-inflammatory effects in RA, and IL37 is an anti-inflammatory cytokine that reduces the immune response and inflammation. This study aimed to investigate serum levels of IL32 and IL73 in RA patients. The sample included 50 patients (46 females and four males) with RA and 40 healthy controls. The enzyme-linked immunosorbent assay (ELISA) detected serum levels of IL32 and IL37. The disease parameters' activity was measured by the clinical disease activity index, and the Erythrocyte sedimentation rate was measured by the Westergren method. Moreover, C-Reactive protein, Rheumatoid factor, and Anti-Cyclic Citrullinated Peptide antibodies were measured using the ELISA. The results showed elevated serum levels of IL32 and IL37 in patients with RA (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.